Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.

Article Details

Citation

Copy to clipboard

Zimhony O, Vilcheze C, Arai M, Welch JT, Jacobs WR Jr

Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.

Antimicrob Agents Chemother. 2007 Feb;51(2):752-4. Epub 2006 Nov 13.

PubMed ID

17101678 [ View in PubMed

]

Abstract

The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.

DrugBank Data that Cites this Article

Drugs

Pyrazinamide

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pyrazinamide	Fatty acid synthetase	Protein	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	Yes	Inhibitor	Details